Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Change in Receivables (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Change in Receivables for 6 consecutive years, with -$2.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 115.04% to -$2.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $898000.0, a 97.5% decrease, with the full-year FY2025 number at $898000.0, down 97.5% from a year prior.
  • Change in Receivables was -$2.2 million for Q4 2025 at PROCEPT BioRobotics, down from $4.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $14.8 million in Q4 2024 to a low of -$3.9 million in Q1 2025.
  • A 5-year average of $4.2 million and a median of $2.6 million in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: tumbled 766.97% in 2021, then soared 631.15% in 2024.
  • PROCEPT BioRobotics' Change in Receivables stood at -$1.9 million in 2021, then surged by 228.78% to $2.4 million in 2022, then skyrocketed by 465.08% to $13.8 million in 2023, then increased by 7.84% to $14.8 million in 2024, then tumbled by 115.04% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Change in Receivables are -$2.2 million (Q4 2025), $4.4 million (Q3 2025), and $2.7 million (Q2 2025).